Player FM 앱으로 오프라인으로 전환하세요!
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.
Manage episode 412653666 series 2739469
We love to hear from our listeners. Send us a message.
This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). From grassroots engagement with physicians and urologists to making a global press to share clinical results, Dr. Reddy offers plenty of insight into biopharma commercial readiness, and good reason to hope for nearly a million NMIBC patients in the U.S. alone.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
챕터
1. Innovative Cancer Treatment Breakthrough (00:00:00)
2. Advancing Cancer Treatments (00:10:26)
3. Navigating Drug Development and Clinical Trials (00:23:36)
4. Shifting to Commercialization Efforts in Biopharma (00:34:12)
5. Bladder Cancer Treatment Costs and Manufacturing (00:39:53)
6. Immunity Bio's Comprehensive Biopharmaceutical Strategy (00:44:23)
219 에피소드
Manage episode 412653666 series 2739469
We love to hear from our listeners. Send us a message.
This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). From grassroots engagement with physicians and urologists to making a global press to share clinical results, Dr. Reddy offers plenty of insight into biopharma commercial readiness, and good reason to hope for nearly a million NMIBC patients in the U.S. alone.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
챕터
1. Innovative Cancer Treatment Breakthrough (00:00:00)
2. Advancing Cancer Treatments (00:10:26)
3. Navigating Drug Development and Clinical Trials (00:23:36)
4. Shifting to Commercialization Efforts in Biopharma (00:34:12)
5. Bladder Cancer Treatment Costs and Manufacturing (00:39:53)
6. Immunity Bio's Comprehensive Biopharmaceutical Strategy (00:44:23)
219 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.